Neurocrine Biosciences Reports 3rd Quarter 2026 Results - NEUROCRINE BIOSCIENCES INC

Financial Performance:

• Achieved record net product sales of >$1.1 billion in Q3 2026, representing a >40% year-over-year increase.
• Non-GAAP earnings per share exceeded $3.00, driven by significant operating leverage.
• Ended the quarter with ~$800 million in cash and generated ~$400 million in operating cash flow.
• Deployed ~$100 million for share repurchases to offset share-based compensation dilution.
• Reported $20 million in timing benefits from customer orders in Q3, expected to reverse in Q4.
• Full-year 2026 Ingrezza sales guidance raised to $2.90–$2.925 billion (from $2.7 billion).

Guidance and Future Outlook:

• Anticipates a "data-rich" 2027 with multiple Phase III readouts for Osepovampator (Osteoporosis), Direclidine (Schizophrenia), and Major Depressive Disorder.
• Expects Ingrezza to deliver double-digit volume growth in 2027, sufficient to offset mid-to-high single-digit net pricing headwinds.
• 2027 full-year sales guidance for Ingrezza expected to be formally released in February 2027.
• Targeting 2027 R&D Day in NYC on December 15 to showcase pipeline progress and PWS data.
• Projecting continued revenue growth across all three commercial products (Ingrezza, Chronicity, Vicat XR) into 2027 and beyond.

Business Segments and Product Lines:

• Ingrezza: Q3 sales of $801 million (+17% YoY); nine years post-launch maintaining double-digit prescription growth; reaching ~50% of diagnosed TD population.
• Chronicity: Q3 sales of $211 million; >15% market penetration of classic Congenital Adrenal Hyperplasia (CAH); 50% of patients are now adults.
• Vicat XR: Q3 sales of $107 million (+$100 million milestone); sequential growth driven by new patient starts despite recent safety reporting fluctuations.
• Pipeline Initiatives: Launched Phase II for NBI-567 (Alzheimer's); initiated Phase I for NBIP-1968 (Obesity); CRF2 agonist MBIP-2118 in Phase I; NBI-223 (Friedreich's ataxia) expected in Phase I in 2027.
• Pipeline Discontinuations: Paused development of NBI-986 (M4 antagonist for movement disorders) due to not meeting phase II bar in aggregate data.

Market and Competitive Landscape:

• Ingrezza faces a competitive landscape but maintains differentiation against CoBEN-VI (Ezicore) regarding side effects and dosing convenience for schizophrenia; noted AbbVie's Imraquity in schizophrenia space.
• Chronicity set the "high bar" for CAH treatment, with Vertex's Kinetics candidate emerging as a future competitor, but Neurocrine highlights superior long-term safety data and physiological dosing control.
• Ingrezza targeting expansion into psychiatry, neurology, and long-term care segments with a focus on advanced practice providers.
• Vicat XR remains the only FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS) patients aged four+.

Risks and Challenges:

• Safety & Reimbursement: Vicat XR facing potential growth delays due to post-marketing safety reporting and patient discontinuation trends; ongoing FDA collaboration to study use in patients with complex comorbidities.
• Pricing Headwinds: Anticipated mid-to-high single-digit net price concessions for Ingrezza in 2027 due to payer contracting dynamics.
• Clinical Execution: Reliance on successful Phase III readouts for Direclidine (Schizophrenia) and Osteo-Vampator (Osteoporosis) to drive future growth.
• Patent Litigation: Potential generic challenge to Vicat XR via 895 patent post-grant review, though company expresses confidence in exclusivity through mid-2040s.

Management Commentary and Tone:

• CEO Kyle Gano expressed "deep confidence" in the strategy, citing record profitability and execution as evidence of a transformative period approaching.
• Tone is optimistic and data-driven, emphasizing the transition to a diversified biopharma with a broad pipeline.
• CMO Irie Roberts returned to the role, expressing excitement to build on the "deepest and most diversified pipeline" in company history.
• Management highlighted record R&D productivity, noting 6 new Phase I and 5 new Phase II starts in a single year.

Analyst Questions and Answers:

• Ingrezza Q4/Lumpy Factors: Q3 beat was driven by volume and record prescriptions; $20M order timing benefit excluded, Q4 expected to seasonally slow but momentum remains strong.
• Vicat XR Safety/Growth: Growth may be slightly delayed by recent safety events, but long-term conviction remains strong; focus on physician education and real-world data generation.
• Chronicity Persistency: High patient persistence (above industry average) drives steady growth; ~15% market penetration reached with significant upside in adult populations.
• Obesity Strategy: Dual approach with subcutaneous weekly CRF2 agonist (MBIP-2118) and Triple G agonist (NBIP-1968); potential for combination therapy to optimize efficacy and safety.
• Schizophrenia Outlook: Confidence in Direclidine's Phase III success hinges on safety/tolerability and novel M4 mechanism; aiming for best-in-class profile vs. current market standards.

Other Key Points:

• Announced a Phase III study for Direclidine in Schizophrenia and a Phase II for NBI-567 in Alzheimer's.
• Initiated a pediatric study for Chronicity to expand the label to patients under four years old.
• Discussed Salesforce expansion impact, expecting full productivity gains to materialize in Q4 and 2027.
• Reaffirmed M&A discipline, seeking differentiated science in neurology, psychiatry, and endocrinology, though no immediate deal urgency.
• Noted that ~50% of patients on Chronicity are now adults, indicating successful expansion beyond the pediatric market.